Dados B3 › AGXY3 × AMER3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | AGXY3 | AMER3 | year |
|---|---|---|---|
| ROE | 9.6% | 4.3% | 2021 |
| ROIC | 15.5%! | -91.0%! | 2022 |
| ROA | -53.2% | 37.2% | 2024 |
| Gross margin | -1.3% | 32.2% | 2024 |
| EBIT margin | -42.8% | 4.5% | 2024 |
| Net margin | -65.5% | 57.7% | 2024 |
| Net debt/EBITDA | 1.52x | 2.63x | 2021 |
| Current ratio | 0.35x | 1.62x | 2024 |
| Revenue growth (1y) | -50.9% | -2.8% | 2024 |
| Revenue growth (5y CAGR) | 24.3% | 16.2% | 2024 |
| Piotroski F-Score | 2/9 | 6/9 | 2024 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | AGXY3 | AMER3 | year |
|---|---|---|---|
| P/E | -0.76x | -3.81x | 2023 × 2025 |
| P/B | 0.26x | 0.22x | 2023 × 2025 |
| EV/EBITDA | 3.36x | 1.73x | 2023 × 2025 |
| FCF yield | -28.2% | 34.5% | 2023 × 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:45 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it